CTLA4 and neoplasm: The use of immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) prior to or in parallel with bispecific antibody administration represents a rational therapeutic strategy, as these drugs relieve immunosuppressive signals from tumor-infiltrating lymphocytes, creating favorable conditions for subsequent activation by bispecific constructs.